65 results about "Glucose uptake" patented technology

The invention provides camel milk active peptide and application thereof in preparation of drugs and edible products for treating and / or preventing diabetes mellitus. Two polypeptide compounds are obtained from papain enzymolysis products of fresh camel milk. Bioactivity evaluation shows that the polypeptide compound has remarkable protein tyrosine phospholipase 1B (PTP1B) inhibitory activity, can enhance insulin receptor sensitivity and promote hepatocyte glucose uptake, has patent medicine potential in the aspect of treating type II diabetes, and can be used for preparing medicines for treating type II diabetes. And a new material basis is provided for developing innovative medicines for treating type II diabetes and developing innovative PTP1B inhibitor hypoglycemic medicines.

A computer-implemented method for treating a patient suffering from Type I Diabetes (T1D). The method can include quantifying physical activity (PA) of the patient; calculating an accumulated PA periodically based on the quantified PA, the accumulated PA indicating an aggregate of the PA; and generating an activity informed insulin bolus by adjusting a prevalent functional insulin therapy bolus with a previous activity component, wherein the previous activity component is based on the accumulated daily PA, an activity profile, and an activity factor of the patient. The method can include determining an additional glucose uptake within a time period, the additional glucose uptake being caused by a PA; translating the additional glucose uptake into a number of insulin units with a same BG lowering impact; and generating an activity informed insulin bolus by adjusting a prevalent functional insulin therapy bolus with the insulin units.

Disclosed here is the method of treating general inflammation, metabolic health / insulin resistance / glycemic-glucose uptake & management (affecting skeletal muscle, liver, adipose, skin, gut, fibro-connective / joint, kidney, brain / CNS and other tissues), systemic inflammation, Immuno-modulation & Metabolic Syndrome / Nonalcoholic fatty liver disease (NAFLD), and provide Immuno-modulation, Insulin Sensitizing and Immuno-Metabolic benefits with at least one short fatty acid, such as butyrate or butyric acid in form of tributyrin, used in conjunction with one cannabinoid, such as cannabidiol or CBD, and with at least one terpene, such as beta-caryophyllene or BCP.

The invention provides an application of liquiritin in preparation of a PPAR gamma receptor partial agonist. Through a structure-based high-throughput virtual screening technology, it is found that liquiritin can be used as a partial agonist of a PPAR gamma receptor, and the relative activation efficiency of liquiritin is 35.9% of that of rosiglitazone; in-vitro experiments prove that liquiritin can remarkably promote glucose uptake and consumption of HepG2 cells and does not induce adipocyte differentiation; in-vivo experiments prove that liquiritin can effectively improve the blood glucose level of an insulin resistance mouse model induced by high fat diet and reduce the level of serum proinflammatory factors. Compared with thiazolidinedione compounds, liquiritin not only can relieve and treat insulin resistance or related metabolic diseases, but also does not cause adverse reactions such as weight gain, fat accumulation and myocardial hypertrophy, provides a new candidate compound for developing safe and effective anti-diabetic drugs, and has a wide application prospect.

The invention relates to the technical field of insulin resistance, in particular to an insulin resistance method for promoting a signal channel based on CTRP9. The method comprises the following steps: constructing a human hepatocyte line plasmid; carrying out cell culture and transfection; detecting the influence of CTRP9 on LO human hepatocyte glucose uptake, PGC-1a gene expression and the phosphorylation level of insulin signal channel related protein; detecting the influence of CTRP9 on glucose uptake of an LO human hepatocyte insulin resistance model, PGC-1a gene expression and the phosphorylation level of insulin signal channel related protein; and carrying out SirT1 / PGC-1a protein expression detection. According to the insulin resistance method for promoting the signal channel based on the CTRP9, a human hepatocyte line is taken as an in-vitro research object, an in-vivo research environment is simulated, a corresponding insulin resistance model is established, and the insulin resistance can be obtained by using technologies such as flow cytometry analysis, RT-PCR (Reverse Transcription-Polymerase Chain Reaction), western blotting and signal channel inhibition. And the treatment effect of CTRP9 on hepatic cell insulin resistance and the specific action mechanism are researched.

The invention discloses hippophae rhamnoides polysaccharide with the activity of reducing blood sugar and blood fat as well as a preparation method and application thereof. Adding water into the degreased hippophae rhamnoides, adjusting the pH value to be acidic, then heating, stirring and extracting under an ultrasonic condition, and collecting filtrate; and performing post-treatment to obtain the sea-buckthorn polysaccharide. The content of neutral sugar in the sea buckthorn polysaccharide is 25.31%-30.68%, the content of uronic acid in the sea buckthorn polysaccharide is 54.66%-59.79%, and the content of protein in the sea buckthorn polysaccharide is 1.91%-2.14%. According to the method, the sea-buckthorn polysaccharide is extracted by adopting acid assistance-ultrasonic extraction, and the prepared sea-buckthorn polysaccharide has remarkable blood sugar and blood fat reducing activity. When the concentration of the sea-buckthorn polysaccharide is as low as 0.1 mg / mL, the glucose uptake of HepG2-IR cells can still be obviously improved, and the content of total cholesterol and total triglyceride of the HepG2-IR cells can be obviously reduced. The hippophae rhamnoides polysaccharide can be applied to preparation of food or medicine for reducing blood sugar and / or blood fat.

A composition for enhancing ATPase activity and supplementing ATP, and a preparation method therefor and the use thereof. The composition comprises the following raw materials: Poria cocos, Rosae rugosae flos, Lycii fructus, Citri reticulatae pericarpium, Morus alba fructus, Jujubae fructus, Polygonati odorati rhizoma, Dimocarpus longan, Polygonati rhizoma and Asini corii colla. The method for preparing the composition product comprises the following steps: (1) selecting one or several raw materials in a formulation, separately soaking the raw materials in a solvent of 5-30 times the amount of the raw materials for 10 min to 5 h, and then performing heating extraction 1-4 times, each time for 10 min to 5 h, so as to obtain extracts; (2) combining the extracts, and concentrating same into a thick paste; and (3) dissolving Asini corii colla by adding an appropriate amount of water, and uniformly mixing same with the thick paste. The product is used for improving glucose uptake, enhancing ATPase activity and increasing cellular ATP content.

The invention discloses a combination of a glutathione synthesis inhibitor and a glucose uptake inhibitor, a nanoparticle delivery system and application thereof, and belongs to the field of medicines. The invention proves that the SLC7A11 is remarkably overexpressed in lung adenocarcinoma and is related to poor clinical prognosis; experiments find that the combination of the glutathione synthesis inhibitor and the glucose uptake inhibitor shows an effect of enhancing lung adenocarcinoma treatment in medium and high SLC7A11 expression cells, and can also achieve an effect equivalent to glucose deprivation under the condition of SLC7A11 overexpression in low expression cells. In order to optimize a delivery mode and minimize systemic toxicity, the invention also prepares a dual-cell membrane coated dual-drug nanoparticle delivery system, the system shows the ability to enhance tumor targeting and drug controllable release, effectively solves the problem of expression difference (heterogeneity) of SLC7A11 in tumors, and shows a significant anti-tumor effect in a preclinical model, and the system has good application prospects. And a promising treatment method is provided for treating lung adenocarcinoma.

The invention relates to a hyaluronic acid high-yield strain based on metabolic flow optimization as well as a construction method and application thereof, and belongs to the technical field of genetic engineering. According to the corynebacterium glutamicum, sources of key rate-limiting enzymes UDP-glucose dehydrogenase and glutamine-fructose-6-phosphate aminotransferase are screened, and heterologous expression of hyaluronic acid synthase and overexpression of endogenous inositol permease and glucokinase are combined, so that the corynebacterium glutamicum capable of highly producing hyaluronic acid is constructed in a form of optimizing metabolic flux; according to the invention, the hyaluronic acid is used as a substrate, polyhydroxybutyrate synthase clusters are further overexpressed in the substrate, the glucose uptake and utilization efficiency of a host are improved, the metabolic coupling of cofactors is realized, the yield of the hyaluronic acid reaches 45g / L, the production intensity is 1.25 g / L / h, a brand new tool is provided for the production of the hyaluronic acid, and the method has an excellent application prospect.

An agent is for inhibiting glucose uptake into red blood cells and a blood collection tube suppresses glucose concentration decrease. The agent for inhibiting glucose uptake into red blood cells includes inosine as an active ingredient. The inhibition agent can be used for suppressing a decrease in glucose concentration of whole blood collected in a blood collection tube. The blood collection tube includes inosine in an internal space. The blood collection tube can be used to measure glucose concentration in blood. The blood collection tube can further include a glycolysis inhibitor.

The method comprises the following steps: amplifying SIRT3 and SIRT4 genes from human, cloning the SIRT3 and SIRT4 genes to a plasmid vector to construct a pSIRT3-4 plasmid, and mediating the simultaneous expression of the two genes by using an internal ribosome entry site (IRES). According to the present invention, the insulin resistance (IR) model of the HepG2 cell is established by using the 35mM high glucose solution, and after the transfection of the pSIRT3-4 plasmid, the uptake of glucose is improved, the conduction of the insulin signal is recovered, the sensitivity of the HepG2 cell to the insulin is improved, the IR is improved, and the dysfunction of the mitochondria is recovered. The pSIRT3-4 plasmid is wrapped by insulin-coupled cationic liposome and is applied to an IR mouse model, and research proves that lipid accumulation in the IR mouse liver is obviously reduced, and the mitochondrial function of the IR mouse liver is obviously improved. The pSIRT3-4 plasmid constructed by the invention provides a new gene therapy means for the treatment of insulin resistance.

The invention discloses a compound polysaccharide preparation for treating diabetes and application thereof, and belongs to the technical field of biomedicine. The compound polysaccharide preparation is composed of compound polysaccharide A and compound polysaccharide B according to the mass ratio of 1: 1. The compound polysaccharide A is prepared from abelmoschus esculentus and chlorella through alkaline ultrasonic extraction and 10-100kDa ultrafiltration classification; the compound polysaccharide B is prepared by performing enzymolysis and hot water extraction on grifola frondosa and sarcodon aspratus. Experiments prove that the preparation can significantly improve insulin secretion and glucose uptake ability of islet cells, effectively reduce fasting blood-glucose of type 2 diabetes model mice and synchronously improve triglyceride and total cholesterol levels through strong synergistic interaction among the components. The preparation disclosed by the invention is natural in source, safe and efficient, so that a new choice is provided for medicine development of type 2 diabetes mellitus.

Described herein is a novel, mitochondrial encoded, open reading frame, that leads to the production of a new mitochondrial peptide. Residing within the ND-Two subunit, a specific small nucleotide polymorphism disrupts expression of this mitochondrial peptide, and is correlated with an increase in obesity and diabetes, particularly in certain ethnic populations. In vitro administration of the peptide increases insulin secretion, decreases fat accumulation and improves glucose uptake in muscle cell. Antibodies generated against the peptide can be used for detecting peptide deficiency, in addition to SNP detection, supporting diagnostic approaches. In vivo studies further revealed that administration of the peptide improves glucose tolerance, thereby providing a new therapeutic avenue for a novel diabetes therapy and decreases bodyweight, thus serving as a novel obesity therapy. Generation of synthetic analogs further enhance or abrogated activity relative to the natural peptide.

The invention provides a probiotic compound for inhibiting anaphylactic reaction. The probiotic compound is prepared from 5 to 15 parts of lactobacillus rhamnosus, 20 to 30 parts of lactobacillus paracasei, 5 to 15 parts of bifidobacterium animalis subsp. Lactis, 1 to 5 parts of bifidobacterium breve, 1 to 5 parts of lactobacillus acidophilus, 1 to 5 parts of plant lactobacillus, 1 to 5 parts of sake lactobacillus brevis, 1 to 5 parts of bifidobacterium longum subsp. Longum and 40 to 55 parts of fructo-oligosaccharide. The probiotic compound is fermented in intestinal tracts to generate metabolite-short-chain fatty acid (consisting of fatty acid with 1-6 carbon atom main chains); the short-chain fatty acid has an anti-inflammatory effect and can enhance an immune protection barrier, such as induction of expansion and de novo differentiation of regulatory T cells; the short-chain fatty acid is a molecule necessary for a B cell differentiation process, and can increase the intake of glucose and promote up-regulation of CXCR < 5 + > and PD-1, so that the growth and development of Tfh cells are realized, and the effect of improving anaphylactic reaction is achieved.

The present application relates to the field of medical detection, in particular to a probe combination for full-spectrum flow cytometry detection of cell metabolism and application thereof. Traditional flow cytometry is limited by fluorescence channel overlap and cannot simultaneously detect multiple metabolic states in the same sample, affecting detection efficiency and data accuracy. The present application optimizes the probe combination and uses full-spectrum flow cytometry to achieve simultaneous detection of two or more metabolic probes, simultaneously detecting multiple metabolic indicators such as intracellular fatty acid uptake, glucose uptake, active oxygen level, and mitochondrial function, and ensuring the compatibility of fluorescence signals between probes. The method of the present application can reduce sample consumption and improve detection efficiency, and is suitable for metabolic analysis of trace clinical samples and rare cell populations, and is widely used in the fields of tumor research, metabolic disease monitoring, drug screening, etc., and provides an efficient and accurate technical means for single-cell level metabolic research.

This invention relates to peptide complexes with anti-diabetic activity and their uses. The peptide complexes of this invention promote cellular glucose uptake, inhibit insulin resistance signaling, promote insulin sensitivity signaling, and inhibit apoptosis of pancreatic β-cells, which are insulin-producing cells, thereby exhibiting a blood glucose-lowering effect. Furthermore, this invention also relates to peptides with anti-diabetic and anti-obesity activities and their uses. The peptides of this invention have activities that inhibit insulin resistance signaling, promote insulin sensitivity signaling, and promote lipolysis in adipocytes.

The invention discloses a nanoliter reactor responding to extracellular L-tryptophan concentration as well as a preparation method and application of the nanoliter reactor. The method comprises the following steps: firstly, transforming escherichia coli through metabolic engineering to construct a sensor strain, and knocking out glucose uptake related genes to form a carbon source orthogonality; l-tryptophan synthesis related genes are inactivated, so that the growth of the L-tryptophan completely depends on exogenous L-tryptophan; next, xylose is replaced by a biosensor element capable of responding to L-tryptophan by using a promoter of a gene, and then a constitutive expression fluorescent protein gene is inserted, so that positive correlation between fluorescence output of a sensor strain and the concentration of L-tryptophan is realized. The sensor bacteria and L-tryptophan producing bacteria are jointly encapsulated in sodium alginate gel microspheres to prepare a nano-liter-scale reactor, so that co-culture of the two strains in the same microenvironment is realized. The overall fluorescence intensity of the microspheres can visually reflect the ability of producing bacteria to synthesize and release L-tryptophan.

This invention relates to the field of biomedical technology, specifically to the application of TXNIP gene expression inhibitors in the preparation of drugs for treating primary biliary cholangitis. This invention discovers the complete mechanism by which hepatocytes regulate glucose uptake through TXNIP, thereby influencing T cell metabolism and driving Th1 differentiation, thus exacerbating intrahepatic inflammation in primary biliary cholangitis (PBC). This clarifies TXNIP as a potential new target for intervening in the progression of PBC, and therefore proposes the application of TXNIP gene expression inhibitors in the preparation of drugs for treating PBC.

The present technology comprises pharmaceutical compositions of non-naturally occurring melanocortin analogs formulated for oral administration. The non-naturally occurring melanocortin analogs may be agonists or antagonists of the melanocortin 5 receptor (MC5R) with sub-micromolar or low-nanomolar binding activity. In some embodiments, the pharmaceutical compositions are formulated to deliver about 0.1 mg / kg to about 5 mg / kg, per body weight of a subject.

The invention provides gynura divaricata polysaccharide as well as a preparation method and application thereof, and belongs to the field of polysaccharide preparation. The homogeneous component GDP1 of the gynura divaricata polysaccharide is mainly prepared from fructose, glucose, arabinose and galactose according to the molar ratio of 58.4: 39.08: 0.75: 0.78; the molecular weight Mw is 6684Da, and the purity is 99.04%; t2DM mouse in-vivo hypoglycemic activity research is carried out, and the prepared gynura divaricata polysaccharide can relieve the symptom of weight loss of mice, relieve the hyperglycemia and insulin resistance level of the mice and regulate the abnormal conditions of the blood fat level, the oxidative stress level and the inflammation level of the mice. The PI3K / Akt / GLUT-4 signal channel is activated to increase the glucose uptake of the T2DM mouse and reduce the insulin resistance of the T2DM mouse, so that the blood glucose metabolism of the T2DM mouse is improved. The gynura divaricata polysaccharide can be used for preparing medicines for treating type 2 diabetes mellitus.

The purpose of the present invention is to provide: a glucose uptake suppressor for red blood cells; and a blood collection tube for suppressing a decrease in glucose concentration. According to the present invention, it is possible to provide a glucose uptake suppressor for red blood cells, which contains inosine as an active ingredient. The repressor according to the present invention can be used to suppress a decrease in the glucose concentration of whole blood collected into a blood collection tube. According to the present invention, it is also possible to provide a blood collection tube having inosine in the internal space. The blood collection tube can be used for measuring the concentration of glucose in blood. The blood collection tube can further comprise a glycolytic system suppressor.

Provided herein are nucleic acids comprising at least one miRNA binding nucleotide sequence, vectors (e.g., AAV) comprising nucleic acids with at least one miRNA binding nucleotide sequence for inhibiting miRNAs that bind to a 3' UTR of an MG29 gene and methods of using the same to prevent or treat metabolic disorders, such as diabetes.

The present application discloses the use of SUR2 receptor modulators. In the present application, SUR2 receptor modulators (e.g. MLC1) can be combined with skeletal muscle cell K ATP SUR2 specific binding on potassium ion channel, thus enhancing intracellular calcium signal, increasing glucose uptake of skeletal muscle cell and reducing blood glucose, and thus can be used as a therapeutic drug for diabetes; SUR2 receptor modulators selectively bind to SUR2 through a non-islet β cell dependent mechanism, and have no inhibitory effect on islet β cell SUR1 receptor, and thus can effectively avoid hypoglycemia while reducing blood glucose, and have small side effects.

The invention discloses dendrobium officinale oligosaccharide as well as a preparation method and application thereof, and belongs to the technical field of preparation of functional components of natural products. According to the invention, by optimizing the process conditions of enzymolysis of dendrobium officinale polysaccharide by beta-mannase, including substrate concentration, enzyme dosage, pH, temperature and time, and purifying, the dendrobium officinale oligosaccharide (DOO1) with the molecular weight of about 921 Da, the molar ratio of mannose to glucose of about 4.53: 1 and the main glucosidic bond of-> 4)-beta-D-Manp-(1->) is obtained. According to the prepared dendrobium officinale oligosaccharide, the solubility and bioavailability of the dendrobium officinale oligosaccharide are remarkably improved, the good alpha-amylase inhibitory activity is shown, the effect of improving insulin to resist cell glucose uptake is achieved, and the functional application potential of dendrobium officinale is further expanded.

The invention relates to the technical field of medicine and chemistry, and particularly discloses an isopentenyl flavonoid compound derived from Morus nigra L. as well as a preparation method and application of the isopentenyl flavonoid compound. The isopentenyl flavonoid compound can remarkably promote glucose uptake and effectively improve the glucose uptake capacity of insulin-resistant cells, so that the isopentenyl flavonoid compound has application potential in the aspect of preparing the medicine for treating diabetes mellitus and can be used for preparing the medicine for treating diabetes mellitus.

The invention provides application of a TNFRSF13B gene in regulating and controlling the adaptive capacity of Hu sheep to a drought environment, and belongs to the technical field of molecular breeding. The invention provides an application of a TNFRSF13B gene in regulating and controlling the adaptive capacity of Hu sheep to a drought environment. Reduction of TNFRSF13B gene expression leads to enhancement of lipid synthesis capability and glucose uptake capability of Hu sheep liver cells and reduction of lipid decomposition capability, and after Hu sheep is introduced into the Hetian region in the arid region and the Taihu Lake region, in order to well adapt to local climatic environment, the Hu sheep becomes smaller in body form and is also improved in lipid synthesis capability, the Hu sheep is reduced in lipid decomposition capability. Therefore, in order to adapt to the drought environment, the TNFRSF13B gene has high methylation and low expression and participates in a signal channel of energy metabolism, and reference is provided for improving the ability of sheep to adapt to the drought environment.

The present technology is directed to managing blood glucose levels in patients and associated systems and methods. For example, the present technology provides a method for decreasing blood glucose levels in patients by delivering electrical signals to a spinal column of the patient via an implanted signal delivery device. The stimulation induces motor contractions in the lower extremity or abdomen, thus causing glucose uptake from the bloodstream in an insulin-independent manner.

The invention relates to the field of medical detection, in particular to a probe combination for full-spectrum flow detection of cell metabolism and application of the probe combination. Traditional flow cytometry is limited by overlapping of fluorescence channels, multiple metabolic states cannot be detected in the same sample at the same time, and detection efficiency and data accuracy are affected. By optimizing the probe combination and utilizing the full-spectrum flow cytometry, synchronous detection of two or more metabolic probes can be realized, multiple metabolic indexes such as fatty acid uptake, glucose uptake, active oxygen level, mitochondrial function and the like in cells can be detected at the same time, and the compatibility of fluorescence signals among the probes is ensured. The method provided by the invention can reduce sample consumption and improve detection efficiency, is suitable for metabolism analysis of trace clinical samples and rare cell populations, is widely applied to the fields of tumor research, metabolic disease monitoring, drug screening and the like, and provides an efficient and accurate technical means for metabolism research at a single cell level.

This invention relates to the biomedical field, specifically to interventional peptides for preparing drugs to treat diabetes, comprising: (a) SEQ ID No. 1; (b) a fusion protein formed by peptide (a) and a transmembrane peptide element; and (c) a peptide derivative of peptide (a) or (b) by deletion, insertion, or substitution of one or more amino acids, and having the same biological function as the peptide molecule described in (a) or (b). This invention has undergone extensive screening and validation at the cellular level and in animal experiments, and has also been tested using serum samples from clinical patients, confirming that the peptides can specifically lower blood glucose levels, promote cellular glucose uptake, and promote glycogen synthesis, thereby improving diabetes symptoms; it only affects glucose metabolism, therefore has few side effects, a long half-life, and significant clinical implications.

The present invention relates to a device (12) for determining a state of health of a patient (11), comprising: an input interface (16) for receiving a glucose measurement value with information relating to a glucose level of the patient and a glucose uptake input value with information relating to a glucose uptake of the patient; an estimation unit (18) for determining the state of health of the patient on the basis of the received values and a predefined state model, which represents the state of health of the patient by means of a state vector and using a plurality of model parameters, wherein the state vector comprises a glucose model value with information relating to the glucose level of the patient and can comprise an insulin model value with information relating to the insulin level of the patient; a comparison unit (20) for determining a deviation between the glucose measurement value and the glucose model value; and an individualization unit (22) for the patient-specific update of a model parameter on the basis of the determined deviation. Further model parameters can comprise individual glucose or insulin sensitivities, the incretin sensitivity and sensitivities with respect to lifestyle input values. The present invention also relates to a system (10) and to a method for determining a state of health of a patient (11).